within Pharmacolibrary.Drugs.ATC.B;

model B05CA10
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.7777777777777776e-07,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>ElectrolytesInCombination</td></tr><tr><td>ATC code:</td><td>B05CA10</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>15</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1000</td><td>milliliter/hour</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>This drug group includes intravenous solutions containing combinations of electrolytes, such as sodium, potassium, calcium, magnesium, and chloride, used for correction of electrolyte imbalances, dehydration, and as vehicles for other drugs. These solutions are widely used for fluid and electrolyte replenishment and are approved and currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for multi-electrolyte intravenous solutions in healthy adults. Since these are aqueous electrolyte solutions, distribution is almost immediate, and elimination depends on renal function and homeostatic mechanisms. Classic pharmacokinetic modeling parameters such as volume of distribution and clearance are generally not applicable in the traditional sense for electrolyte solutions, but basic estimated values can be provided.</p><h4>References</h4><ol><li><p>Bateman, RM, et al., &amp; Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. <i>Critical care (London, England)</i> 20(Suppl 2) 94–None. DOI:<a href=\"https://doi.org/10.1186/s13054-016-1208-6\">10.1186/s13054-016-1208-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27885969/\">https://pubmed.ncbi.nlm.nih.gov/27885969</a></p></li><li><p>Levitskaia, TG, et al., &amp; Thrall, KD (2010). Biomaterials for the decorporation of (85)Sr in the rat. <i>Health physics</i> 99(3) 394–400. DOI:<a href=\"https://doi.org/10.1097/HP.0b013e3181c4717d\">10.1097/HP.0b013e3181c4717d</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20699703/\">https://pubmed.ncbi.nlm.nih.gov/20699703</a></p></li><li><p>Yang, S, et al., &amp; Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). <i>Clinical pharmacokinetics</i> 60(7) 887–896. DOI:<a href=\"https://doi.org/10.1007/s40262-021-00988-1\">10.1007/s40262-021-00988-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33598874/\">https://pubmed.ncbi.nlm.nih.gov/33598874</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end B05CA10;
